兄弟科技(002562.SZ)擬使用4.14億元募集資金對兄弟醫藥提供借款
格隆匯1月10日丨兄弟科技(002562.SZ)公佈,公司“年產30,000噸天然香料建設項目”實施主體為兄弟醫藥,兄弟醫藥是公司全資子公司。為保證募投項目順利實施,公司擬使用4.14億元募集資金對“年產30,000噸天然香料建設項目”實施主體兄弟醫藥提供借款,以保障募集資金投資項目的順利實施,借款利率參照央行公佈LPR貸款市場報價利率,借款期限為7年,還款視兄弟醫藥資金情況隨還。
本次使用募集資金向全資子公司提供借款,是基於募投項目實施主體建設需要,有利於保障募投項目順利實施,募集資金的使用方式和用途等符合公司的發展戰略以及相關法律法規的規定,符合公司及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.